Table of Contents
Advances in Molecular Biology
Volume 2014, Article ID 471635, 11 pages
http://dx.doi.org/10.1155/2014/471635
Research Article

Beta2-Adrenergic Receptor Gene Polymorphisms in Egyptian Patients with Acute Myocardial Infarction

1Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt
2Department of Chest Diseases, Faculty of Medicine, Cairo University, Giza, Egypt
3Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt

Received 31 July 2014; Revised 8 November 2014; Accepted 17 November 2014; Published 9 December 2014

Academic Editor: Piero R. Bianco

Copyright © 2014 Eman Toraih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. Wang, S.-B. Zhou, and L.-J. Wang, “Seven functional polymorphisms in the CETP Gene and myocardial infarction risk: a meta-analysis and meta-regression,” PLoS One, vol. 9, no. 2, Article ID e88118, 2014. View at Publisher · View at Google Scholar
  2. K. Thygesen and J. Searle, “Update on the universal definition of acute myocardial infarction in the light of new data,” Conference Papers in Medicine, vol. 2013, Article ID 479352, 5 pages, 2013. View at Publisher · View at Google Scholar
  3. C. de Zwaan, M. Daemen, and W. Hermens, “Mechanisms of cell death in acute myocardial infarction: pathophysiological implications for treatment,” Netherland Heart Journal, vol. 9, no. 1, pp. 30–44, 2001. View at Google Scholar
  4. D. H. Walter and A. M. Zeiher, “Genetic risk factors for myocardial infarction,” Herz, vol. 25, no. 1, pp. 7–14, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Yamada, H. Izawa, S. Ichihara et al., “Prediction of the risk of myocardial infarction from polymorphisms in candidate genes,” The New England Journal of Medicine, vol. 347, no. 24, pp. 1916–1923, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Visvikis-Siest and J.-B. Marteau, “Genetic variants predisposing to cardiovascular disease,” Current Opinion in Lipidology, vol. 17, no. 2, pp. 139–151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Cao, Y. Z. Ye, J. Rui et al., “A single-nucleotide polymorphism in the proximal promoter region of the apolipoprotein M gene is associated with dyslipidaemia but not increased coronary artery diseases in Chinese populations,” Lipids in Health and Disease, vol. 12, no. 1, article 184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Abraham, O. G. Bhalala, P. I. W. de Bakker, S. Ripatti, and M. Inouye, “Towards a molecular systems model of coronary artery disease,” Current Cardiology Reports, vol. 16, no. 6, article 488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. E. J. Topol, J. Smith, E. F. Plow, and Q. K. Wang, “Genetic susceptibility to myocardial infarction and coronary artery disease,” Human Molecular Genetics, vol. 15, no. 2, pp. R117–R123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Schunkert, J. Erdmann, and N. J. Samani, “Genetics of myocardial infarction: a progress report,” European Heart Journal, vol. 31, no. 8, pp. 918–925, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. A. Hindorff, S. R. Heckbert, B. M. Psaty et al., “β2-adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study,” The American Journal of Hypertension, vol. 18, no. 3, pp. 392–397, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. E. M. Snyder, M. J. Joyner, S. T. Turner, and B. D. Johnson, “Blood pressure variation in healthy humans: a possible interaction with β-2 adrenergic receptor genotype and renal epithelial sodium channels,” Medical Hypotheses, vol. 65, no. 2, pp. 296–299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Y. L. Zee, N. R. Cook, R. Reynolds, S. Cheng, and P. M. Ridker, “Haplotype analysis of the β2 adrenergic receptor gene and risk of myocardial infarction in humans,” Genetics, vol. 169, no. 3, pp. 1583–1587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Yilmaz, M. G. Kaya, U. Merdanoglu, M. A. Ergun, A. Cengel, and S. Menevse, “Association of β-1 and β-2 adrenergic receptor gene polymorphisms with myocardial infarction,” Journal of Clinical Laboratory Analysis, vol. 23, no. 4, pp. 237–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Kulminski, I. V. Culminskaya, S. V. Ukraintseva et al., “Polymorphisms in the ACE and ADRB2 genes and risks of aging-associated phenotypes: the case of myocardial infarction,” Rejuvenation Research, vol. 13, no. 1, pp. 13–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. H. Daghestani, A. Warsy, A. N. Al-Odaib et al., “Arginine 16 glycine polymorphism in β2-adrenergic receptor gene is associated with obesity, hyperlipidemia, hyperleptinemia, and insulin resistance in saudis,” International Journal of Endocrinology, vol. 2012, Article ID 945608, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Guimarães and D. Moura, “Vascular adrenoceptors: an update,” Pharmacological Reviews, vol. 53, no. 2, pp. 319–356, 2001. View at Google Scholar · View at Scopus
  18. H. A. Rockman, W. J. Koch, and R. J. Lefkowitz, “Seven-transmembrane-spanning receptors and heart function,” Nature, vol. 415, no. 6868, pp. 206–212, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. S. R. Heckbert, L. A. Hindorff, K. L. Edwards et al., “β2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly,” Circulation, vol. 107, no. 15, pp. 2021–2024, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Zaugg, M. C. Schaub, T. Pasch, and D. R. Spahn, “Modulation of β-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action,” British Journal of Anaesthesia, vol. 88, no. 1, pp. 101–123, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Johnson and S. B. Liggett, “Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions,” Clinical Pharmacology and Therapeutics, vol. 89, no. 3, pp. 366–378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. A. Johnson and S. G. Terra, “β-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics,” Pharmaceutical Research, vol. 19, no. 12, pp. 1779–1787, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Al-Rubaish, F. Al-Muhanna, A. Al-Shehri et al., “β2-adrenergic receptor gene polymorphisms in normal and in patients with myocardial infarction in the eastern province of Saudi Arabia,” Saudi Journal of Medicine and Medical Sciences, vol. 1, pp. 25–29, 2013. View at Google Scholar
  24. L. P. Svetkey, P. Z. Timmons, O. Emovon, N. B. Anderson, L. Preis, and Y.-T. Chen, “Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype,” Hypertension, vol. 27, no. 6, pp. 1210–1215, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. S.-M. Herrmann, V. Nicaud, L. Tiret et al., “Polymorphisms of the β2-adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies,” Journal of Hypertension, vol. 20, no. 2, pp. 229–235, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Galletti, R. Iacone, E. Ragone et al., “Lack of association between polymorphism in the β2-adrenergic receptor gene, hypertension, and obesity in the Olivetti Heart Study,” The American Journal of Hypertension, vol. 17, no. 8, pp. 718–720, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Iwamoto, M. Ohishi, M. Yuan et al., “β-Adrenergic receptor gene polymorphism is a genetic risk factor for cardiovascular disease: a cohort study with hypertensive patients,” Hypertension Research, vol. 34, no. 5, pp. 573–577, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Forleo, N. Resta, S. Sorrentino et al., “Association of β-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy,” The American Journal of Medicine, vol. 117, no. 7, pp. 451–458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. S. B. Liggett, L. E. Wagoner, L. L. Craft et al., “The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure,” The Journal of Clinical Investigation, vol. 102, no. 8, pp. 1534–1539, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Shin, M. T. Lobmeyer, Y. Gong et al., “Relation of beta (2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure,” American Journal of Cardiology, vol. 99, no. 2, pp. 250–255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Ulucan, V. Cetintas, A. Tetik et al., “β1 and β2-adrenergic receptor polymorphisms and idiopathic ventricular arrhythmias,” Journal of Cardiovascular Electrophysiology, vol. 19, no. 10, pp. 1053–1058, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Sotoodehnia, D. S. Siscovick, M. Vatta et al., “β2-adrenergic receptor genetic variants and risk of sudden cardiac death,” Circulation, vol. 113, no. 15, pp. 1842–1848, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. L. P. Chung, G. Waterer, and P. J. Thompson, “Pharmacogenetics of β2 adrenergic receptor gene polymorphisms, long-acting β-agonists and asthma,” Clinical and Experimental Allergy, vol. 41, no. 3, pp. 312–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. Karam, N. A. Sabbah, H. E. Zidan, and H. M. A. Rahman, “Association between genetic polymorphisms of β2 adrenergic receptors and nocturnal asthma in Egyptian children,” Journal of Investigational Allergology and Clinical Immunology, vol. 23, no. 4, pp. 262–266, 2013. View at Google Scholar · View at Scopus
  35. A. C. Z. de Paiva, F. A. D. L. Marson, J. D. Ribeiro, and C. S. Bertuzzo, “Asthma: gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors,” Allergy, Asthma and Clinical Immunology, vol. 10, no. 1, article 8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Hesse and J. H. Eisenach, “Genetic variation in the β2-adrenergic receptor: impact on intermediate cardiovascular phenotypes,” Current Pharmacogenomics and Personalized Medicine, vol. 6, no. 3, pp. 160–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. A. M. Al-Rubaish, “Association of beta2-adrenergic receptor gene polymorphisms and nocturnal asthma in Saudi patients,” Annals of Thoracic Medicine, vol. 6, no. 2, pp. 66–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Johnson, “Molecular mechanisms of β2-adrenergic receptor function, response, and regulation,” Journal of Allergy and Clinical Immunology, vol. 117, no. 1, pp. 18–24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. A. Litonjua, L. Gong, Q. L. Duan et al., “Very important pharmacogene summary ADRB2,” Pharmacogenetics and Genomics, vol. 20, no. 1, pp. 64–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. S. B. Pereira, I. A. Gava, C. Giro, and E. T. Mesquita, “Adrenergic receptor polymorphisms in heart failure: what can genetics explain?” Arquivos Brasileiros de Cardiologia, vol. 94, no. 6, pp. 841–849, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Masuo and G. W. Lambert, “Relationships of adrenoceptor polymorphisms with obesity,” Journal of Obesity, vol. 2011, Article ID 609485, 10 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. K. S. Adriani, M. C. Brouwer, F. Baas, A. H. Zwinderman, A. van der Ende, and D. van de Beek, “Genetic variation in the β2-adrenocepter gene is associated with susceptibility to bacterial meningitis in adults,” PLoS ONE, vol. 7, no. 5, Article ID e37618, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. O. E. Brodde, “β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses,” Pharmacology and Therapeutics, vol. 117, no. 1, pp. 1–29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Sala, A. di Castelnuovo, L. Cuomo et al., “The E27 β2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males,” Journal of Thrombosis and Haemostasis, vol. 85, pp. 231–233, 2001. View at Google Scholar
  45. S. M. Wallerstedt, A. L. Eriksson, C. Ohlsson, and T. Hedner, “Haplotype association analysis of the polymorphisms Arg16Gly and Gln27Glu of the adrenergic β2 receptor in a Swedish hypertensive population,” Journal of Human Hypertension, vol. 19, no. 9, pp. 705–708, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Thygesen, J. Alpert, and A. Jaffe, “Third universal definition of myocardial infarction,” European Heart Journal, vol. 33, no. 20, pp. 2551–2567, 2012. View at Google Scholar
  47. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, supplement 1, pp. S62–S69, 2010. View at Publisher · View at Google Scholar
  48. Y. Lou, J. Liu, Y. Li et al., “Association study of the β2-adrenergic receptor gene polymorphisms and hypertension in the Northern Han Chinese,” PLoS ONE, vol. 6, no. 4, Article ID e18590, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Trinder, “Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen,” Journal of Clinical Pathology, vol. 22, no. 2, pp. 158–161, 1969. View at Publisher · View at Google Scholar · View at Scopus
  50. C. C. Allain, L. Poon, and C. Chan, “Enzymatic determination of total serum cholesterol,” Clinical Chemistry, vol. 20, no. 4, pp. 470–475, 1974. View at Google Scholar · View at Scopus
  51. B. Roschlau, E. Burnt, and W. Gruber, “Enzymatiche estimmung des cesamt-cholestrins in serum,” Zeitschrift für klinische Chemie und klinische Biochemie, vol. 12, p. 226, 1974. View at Google Scholar
  52. J. Siedel, R. Schmuck, and J. Staepels, “Long-term stable liquid ready-to-use mono reagent for the enzymatic assay of serum or plasma triglycerides (GPO-PAP method),” Clinical Chemistry, vol. 39, AACC meeting, abstract 34., p. 1127, 1993. View at Google Scholar
  53. M. F. Lopes Virella, P. Stone, S. Ellis, and J. A. Colwell, “Cholesterol determination in high density lipoproteins separated by three different methods,” Clinical Chemistry, vol. 23, no. 5, pp. 882–884, 1977. View at Google Scholar · View at Scopus
  54. K. Shashidhar, P. Pareenta, B. Gopalakrishna, and A. Hemalatha, “Lipoprotein (a) and other lipid profile in patients with thrombotic stroke: is it a reliable marker?” Journal of Laboratory Physicians, vol. 3, no. 1, pp. 28–32, 2011. View at Publisher · View at Google Scholar
  55. J. Gennest and P. Libby, “Lipoprotein disorders and cardiovascular disease,” in Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, R. O. Bonow, D. L. Mann, D. P. Zipes, and P. Libby, Eds., chapter 47, Saunders Elsevier, Philadelphia, Pa, USA, 9th edition, 2011. View at Google Scholar
  56. J. Jung, P. Min, H. Park et al., “The effects of the β2-adrenergic receptor gene polymorphism on the risk of essential hypertension,” Korean Circulation Journal, vol. 35, no. 10, pp. 753–758, 2005. View at Google Scholar
  57. A. Blakemore, C. Angela, G. Ana-Maria et al., “IL-Ra allele (IL-1RN*2) associated with nephropathy in diabetes,” Human Genetics, vol. 97, no. 3, pp. 369–374, 1996. View at Publisher · View at Google Scholar
  58. J. Syrjänen, M. Hurme, T. Lehtimäki, J. Mustonen, and A. Pasternack, “Polymorphism of the cytokine genes and IgA nephropathy,” Kidney International, vol. 61, no. 3, pp. 1079–1085, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. A. E. Hegab, T. Sakamoto, W. Saitoh et al., “Polymorphisms of IL4, IL13, and ADRB2 genes in COPD,” Chest, vol. 126, no. 6, pp. 1832–1839, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. D. G. Contopoulos-Ioannidis, E. N. Manoli, and J. P. A. Ioannidis, “Meta-analysis of the association of β2-adrenergic receptor polymorphisms with asthma phenotypes,” Journal of Allergy and Clinical Immunology, vol. 115, no. 5, pp. 963–972, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. K. K. Abu-Amero, O. M. Al-Boudari, G. H. Mohamed, and N. Dzimiri, “The Glu27 genotypes of the Beta2-adrenergic receptor are predictors for severe coronary artery disease,” BMC Medical Genetics, vol. 7, article 31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. H. G. Xie, C. M. Stein, R. B. Kim et al., “Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals,” Pharmacogenetics, vol. 9, no. 4, pp. 511–516, 1999. View at Google Scholar · View at Scopus
  63. T. Limsuwan, A. Thakkinstian, O. Verasertniyom et al., “Possible protective effects of the Glu27 allele of β2-adrenergic receptor polymorphism in Thai asthmatic patients,” Asian Pacific Journal of Allergy and Immunology, vol. 28, no. 2-3, pp. 107–114, 2010. View at Google Scholar · View at Scopus
  64. A. E. Atia, K. Norsidah, A. Nor Zamzila et al., “Preliminary study on association of β2-adrenergic receptor polymorphism with hypertension in hypertensive subjects attending Balok Health Centre, Kuantan,” Medical Journal of Malaysia, vol. 67, no. 1, pp. 25–30, 2012. View at Google Scholar · View at Scopus
  65. M. D'Amato, L. R. Vitiani, G. Petrelli et al., “Association of persistent bronchial hyperresponsiveness with β2-adrenoceptor (ADRB2) haplotypes: a population study,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 6, pp. 1968–1973, 1998. View at Publisher · View at Google Scholar · View at Scopus
  66. C. M. Drysdale, D. W. McGraw, C. B. Stack et al., “Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 19, pp. 10483–10488, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. E. Israel, V. M. Chinchilli, J. G. Ford et al., “Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial,” The Lancet, vol. 364, no. 9444, pp. 1505–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. G. A. Hawkins, K. Tantisira, D. A. Meyers et al., “Sequence, haplotype, and association analysis of ADRβ2 in a multiethnic asthma case-control study,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 10, pp. 1101–1109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Vacca, K. Schwabe, R. Dück et al., “Polymorphisms of the β2 adrenoreceptor gene in chronic obstructive pulmonary disease,” Therapeutic Advances in Respiratory Disease, vol. 3, no. 1, pp. 3–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Leineweber and G. Heusch, “β1- and β2-adrenoceptor polymorphisms and cardiovascular diseases,” British Journal of Pharmacology, vol. 158, no. 1, pp. 61–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. A. M. Kulminski, I. Culminskaya, S. V. Ukraintseva, K. G. Arbeev, K. C. Land, and A. I. Yashin, “Beta2-adrenergic receptor gene polymorphisms as systemic determinants of healthy aging in an evolutionary context,” Mechanisms of Ageing and Development, vol. 131, no. 5, pp. 338–345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. N. Pezzali, A. Curnis, C. Specchia et al., “Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results,” Europace, vol. 15, no. 10, pp. 1475–1481, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. D. M. Kaye, B. Smirk, C. Williams, G. Jennings, M. Esler, and D. Holst, “β-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure,” Pharmacogenetics, vol. 13, no. 7, pp. 379–382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Barbato, A. Berger, L. Delrue et al., “GLU-27 variant of β2-adrenergic receptor polymorphisms is an independent risk factor for coronary atherosclerotic disease,” Atherosclerosis, vol. 194, no. 2, pp. e80–e86, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Li, Y. Zhang, C. Li et al., “HSPA12B attenuates cardiac dysfunction and remodelling after myocardial infarction through an eNOS-dependent mechanism,” Cardiovascular Research, vol. 99, no. 4, pp. 674–684, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Johnson, “The β-adrenoceptor,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 5, pp. S146–S153, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. S. A. Green, J. Turki, P. Bejarano, I. P. Hall, and S. B. Liggett, “Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells,” American journal of respiratory cell and molecular biology, vol. 13, no. 1, pp. 25–33, 1995. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Green, J. Turki, and M. Innis, “Amino-terminal polymorphisms of the human β2-adrenergic receptor impart distinct agonist-promoted regulatory properties,” Biochemistry, vol. 33, pp. 9414–9419, 1994. View at Google Scholar
  79. K. M. Small, D. W. McGraw, and S. B. Liggett, “Pharmacology and physiology of human adrenergic receptor polymorphisms,” Annual Review of Pharmacology and Toxicology, vol. 43, pp. 381–411, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. S. A. Green, G. Cole, M. Jacinto, M. Innis, and S. B. Liggett, “A polymorphism of the human β2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor,” The Journal of Biological Chemistry, vol. 268, no. 31, pp. 23116–23121, 1993. View at Google Scholar · View at Scopus
  81. S. B. Liggett, “β2-Adrenergic receptor pharmacogenetics,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 3, pp. S197–S201, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. L. E. Wagoner, L. L. Craft, B. Singh et al., “Polymorphisms of the β2-adrenergic receptor determine exercise capacity in patients with heart failure,” Circulation Research, vol. 86, no. 8, pp. 834–840, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Iaccarino, R. Izzo, V. Trimarco et al., “β2-Adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension,” Clinical Pharmacology and Therapeutics, vol. 80, no. 6, pp. 633–645, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. V. Sarpeshkar and D. J. Bentley, “Adrenergic-β2 receptor polymorphism and athletic performance,” Journal of Human Genetics, vol. 55, no. 8, pp. 479–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Thakkinstian, M. McEvoy, C. Minelli et al., “Systematic review and meta-analysis of the association between β2-adrenoceptor polymorphisms and asthma: a HuGE review,” American Journal of Epidemiology, vol. 162, no. 3, pp. 201–211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. V. Dishy, G. G. Sofowora, H.-G. Xie et al., “The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization,” The New England Journal of Medicine, vol. 345, no. 14, pp. 1030–1035, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. G. W. Dorn II, “Adrenergic signaling polymorphisms and their impact on cardiovascular disease,” Physiological Reviews, vol. 90, no. 3, pp. 1013–1062, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Schurks, T. Kurth, P. M. Ridker, J. E. Buring, and R. Y. L. Zee, “Association between polymorphisms in the β2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women,” Thrombosis and Haemostasis, vol. 101, no. 2, pp. 351–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. S. M. Wallerstedt, A.-L. Eriksson, C. Ohlsson, and T. Hedner, “Haplotype association analysis of the polymorphisms Arg16Gly and Gln27Glu of the adrenergic β2 receptor in a Swedish hypertensive population,” Journal of Human Hypertension, vol. 19, no. 9, pp. 705–708, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. K. M. Rexrode, P. M. Ridker, H. H. Hegener, J. E. Buring, J. E. Manson, and R. Y. L. Zee, “Genetic variation of the androgen receptor and risk of myocardial infarction and ischemic stroke in women,” Stroke, vol. 39, no. 5, pp. 1590–1592, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. T. E. Hebert, S. Moffett, J.-P. Morello et al., “A peptide derived from a β2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation,” The Journal of Biological Chemistry, vol. 271, no. 27, pp. 16384–16392, 1996. View at Publisher · View at Google Scholar · View at Scopus
  92. D. Ge, J. Huang, J. He et al., “β2-adrenergic receptor gene variations associated with stage-2 hypertension in northern Han Chinese,” Annals of Human Genetics, vol. 69, no. 1, pp. 36–44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. D. W. McGraw, S. L. Forbes, L. A. Kramer, and S. B. Liggett, “Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression,” Journal of Clinical Investigation, vol. 102, no. 11, pp. 1927–1932, 1998. View at Publisher · View at Google Scholar · View at Scopus
  94. A. L. Parola and B. K. Kobilka, “The peptide product of a 5′ leader cistron in the β2 adrenergic receptor mRNA inhibits receptor synthesis,” The Journal of Biological Chemistry, vol. 269, no. 6, pp. 4497–4505, 1994. View at Google Scholar · View at Scopus
  95. K. Bengtsson, M. Orho-Melander, O. Melander et al., “β2-Adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes,” Hypertension, vol. 37, no. 5, pp. 1303–1308, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Binder, E. Garcia, C. Wallace et al., “Haplotypes of the beta-2 adrenergic receptor associate with high diastolic blood pressure in the Caerphilly prospective study,” Journal of Hypertension, vol. 24, no. 3, pp. 471–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. J. R. Cockcroft, A. G. Gazis, D. J. Cross et al., “β2-Adrenoceptor polymorphism determines vascular reactivity in humans,” Hypertension, vol. 36, no. 3, pp. 371–375, 2000. View at Publisher · View at Google Scholar · View at Scopus
  98. I. C. Trombetta, L. T. Batalha, M. U. P. B. Rondon et al., “Gly16 + Glu27 β2-adrenoceptor polymorphisms cause increased forearm blood flow responses to mental stress and handgrip in humans,” Journal of Applied Physiology, vol. 98, no. 3, pp. 787–794, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. U. H. Frey, J. Karlik, F. Herbstreit, and J. Peters, “β2-adrenoceptor gene variants affect vasopressor requirements in patients after thoracic epidural anaesthesia,” British Journal of Anaesthesia, vol. 112, no. 3, pp. 477–484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Candy, N. Samani, G. Norton et al., “Association analysis of β2 adrenoceptor polymorphisms with hypertension in a Black African population,” Journal of Hypertension, vol. 18, no. 2, pp. 167–172, 2000. View at Publisher · View at Google Scholar · View at Scopus
  101. H.-G. Xie, C. M. Stein, R. B. Kim et al., “Human β2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans,” Clinical Pharmacology & Therapeutics, vol. 67, no. 6, pp. 670–675, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. K. Ranade, M. S. Chang, C. T. Ting et al., “High-throughput genotyping with single nucleotide polymorphisms,” Genome Research, vol. 11, no. 7, pp. 1262–1268, 2001. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Ishiyama-Shigemoto, K. Yamada, X. Yuan, F. Ichikawa, and K. Nonaka, “Association of polymorphisms in the β2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus,” Diabetologia, vol. 42, no. 1, pp. 98–101, 1999. View at Publisher · View at Google Scholar · View at Scopus
  104. S. J. Prior, A. P. Goldberg, and A. S. Ryan, “ADRB2 haplotype is associated with glucose tolerance and insulin sensitivity in obese postmenopausal women,” Obesity, vol. 19, no. 2, pp. 396–401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. K. Masuo, T. Katsuya, Y. Fu, H. Rakugi, T. Ogihara, and M. L. Tuck, “β2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals,” American Journal of Hypertension, vol. 18, no. 7, pp. 1009–1014, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. T. J. Chang, M. H. Tsai, Y. D. Jiang et al., “The Arg16Gly polymorphism of human β2-adrenoreceptor is associated with type 2 diabetes in Taiwanese people,” Clinical Endocrinology, vol. 57, no. 5, pp. 685–690, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. A. P. Gjesing, G. Andersen, K. S. Burgdorf et al., “Studies of the associations between functional β2- adrenergic receptor variants and obesity, hypertension and type 2 diabetes in 7,808 white subjects,” Diabetologia, vol. 50, no. 3, pp. 563–568, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. S.-H. Kim, D.-J. Kim, I. A. Seo et al., “Significance of β2-adrenergic receptor gene polymorphism in obesity and type 2 diabetes mellitus in Korean subjects,” Metabolism: Clinical and Experimental, vol. 51, no. 7, pp. 833–837, 2002. View at Publisher · View at Google Scholar · View at Scopus
  109. N. L. Duarte, S. Colagiuri, T. Palu, X. L. Wang, and D. E. L. Wilcken, “Obesity, Type II diabetes and the β2 adrenoceptor gene Gln27Glu polymorphism in the Tongan population,” Clinical Science, vol. 104, no. 3, pp. 211–215, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. S. M. Echwald, T. I. A. Sørensen, A. Tybjærg-Hansen, T. Andersen, and O. Pedersen, “Gln27Glu variant of the human β2-adrenoreceptor gene is not associated with early-onset obesity in Danish men,” Diabetes, vol. 47, no. 10, pp. 1657–1658, 1998. View at Publisher · View at Google Scholar · View at Scopus
  111. H. Wu, H. Bai, P. Fan, R. Liu, Y. Liu, and B. Liu, “Analysis of β2-adrenergic receptor gene (β2-AR) Arg16Gly polymorphism in patients with endogenous hypertriglyceridemia in Chinese population,” Zhonghua Yi Xue Yi Chuan Xue Za Zhi, vol. 25, pp. 50–54, 2008. View at Google Scholar
  112. D. Vercelli, “Discovering susceptibility genes for asthma and allergy,” Nature Reviews Immunology, vol. 8, no. 3, pp. 169–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Kimura, “Genetic analysis of multifactorial cardiac diseases: idiopathic dilated cardiomyopathy and myocardial infarction,” Nippon Ika Daigaku zasshi, vol. 66, no. 5, pp. 332–335, 1999. View at Publisher · View at Google Scholar · View at Scopus